ResearchMoz

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

GBI Research
Published Date » 2014-01-16
No. Of Pages » 90
   
 
 GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics (Irritable Bowel Syndrome, Ulcerative Colitis and Crohn’s Disease) in Major Developed Markets’, which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn’s Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth...
Table of Content

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11

2 Gastrointestinal Therapeutics in Major Developed Markets – Introduction 12
2.1 Irritable Bowel Syndrome 12
2.1.1 Classification 12
2.1.2 Symptoms 12
2.1.3 Etiology 12
2.1.4 Pathophysiology 13
2.1.5 Diagnosis 13
2.1.6 Epidemiology 14
2.1.7 Prognosis 15
2.1.8 Treatment Options 15
2.2 Ulcerative Colitis 16
2.2.1 Classification 16
2.2.2 Symptoms 17
2.2.3 Etiology 17
2.2.4 Pathophysiology 18
2.2.5 Diagnosis 18
2.2.6 Epidemiology 19
2.2.7 Prognosis 19
2.2.8 Treatment Options 20
2.3 Crohn’s Disease 21
2.3.1 Classification 21
2.3.2 Symptoms 22
2.3.3 Etiology 22
2.3.4 Pathophysiology 23
2.3.5 Diagnosis 23
2.3.6 Epidemiology 24
2.3.7 Prognosis 24
2.3.8 Treatment Options 25

3 Gastrointestinal Therapeutics in Major Developed Markets – Marketed Products (Global) 26
3.1 Irritable Bowel Syndrome 26
3.2 Ulcerative Colitis 26
3.3 Crohn’s Disease 26
3.4 Key Marketed Products 27
3.4.1 Amitiza 27
3.4.2 Humira 28
3.4.3 Remicade 29
3.4.4 Simponi 30
3.4.5 Cimzia 31
3.4.6 Tysabri 32

4 Gastrointestinal Therapeutics in Major Developed Markets – Pipeline Analysis 34
4.1 Irritable Bowel Syndrome 34
4.1.1 Overall Pipeline 34
4.1.2 Pipeline Analysis by Molecule Type 36
4.1.3 Pipeline Analysis by Mechanism of Action 37
4.2 Ulcerative Colitis Pipeline 39
4.2.1 Overall Pipeline 39
4.2.2 Pipeline Analysis by Molecule Type 41
4.2.3 Pipeline Analysis by Mechanism of Action 42
4.3 Crohn’s Disease Pipeline 44
4.3.1 Overall Pipeline 44
4.3.2 Pipeline Analysis by Molecule Type 46
4.3.3 Pipeline Analysis by Mechanism of Action 47
4.4 Promising Drug Candidates in the Pipeline 49
4.4.1 GSK-1605786 49
4.4.2 MLN0002 49
4.4.3 EMD-61753 49

5 Gastrointestinal Therapeutics in Major Developed Markets – Market Forecast to 2019 50
5.1 Major Developed Markets 50
5.1.1 Treatment Usage Patterns 50
5.1.2 Annual Cost of Therapy 50
5.1.3 Market Size 50
5.2 US 52
5.2.1 Treatment Usage Patterns 52
5.2.2 Annual Cost of Therapy 52
5.2.3 Market Size 52
5.3 Europe 54
5.3.1 Treatment Usage Patterns 54
5.3.2 Annual Cost of Therapy 54
5.3.3 Market Size 54
5.4 Canada 56
5.4.1 Treatment Usage Patterns 56
5.4.2 Annual Cost of Therapy 56
5.4.3 Market Size 56
5.5 Japan 58
5.5.1 Treatment Usage Patterns 58
5.5.2 Annual Cost of Therapy 58
5.5.3 Market Size 58
5.6 Drivers and Barriers 60
5.6.1 Drivers 60
5.6.2 Barriers 60

6 Gastrointestinal Therapeutics in Major Developed Markets – Deals and Strategic Consolidations (Global) 62
6.1 Deals Analysis 62
6.2 Major Co-Development Deals 64
6.2.1 AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide 65
6.2.2 Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies 65
6.2.3 Galapagos and AbbVie Extend GLPG0634 Development Agreement to Include Crohn's Disease 65
6.3 Major Licensing Deals 66
6.3.1 AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3 Inhibitor Program 67
6.3.2 Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin 67
6.3.3 GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx 67

7 Gastrointestinal Therapeutics in Major Developed Markets – Appendix 68
7.1 All Pipeline Drugs by Phase 68
7.1.1 Discovery 68
7.1.2 Preclinical 68
7.1.3 IND/CTA-filed 69
7.1.4 Phase I 70
7.1.5 Phase II 71
7.1.6 Phase III 73
7.1.7 Pre-Registration 73
7.1.8 Undisclosed 74
7.2 Market Forecasts to 2019 74
7.2.1 Major Developed Markets 74
7.2.2 US 75
7.2.3 Canada 76
7.2.4 UK 77
7.2.5 France 78
7.2.6 Germany 79
7.2.7 Italy 80
7.2.8 Spain 81
7.2.9 Japan 82
7.3 Market Definitions 83
7.4 Abbreviations 83
7.5 Sources 85
7.6 Research Methodology 87
7.6.1 Coverage 87
7.6.2 Secondary Research 87
7.6.3 Primary Research 88
7.6.4 Therapeutic Landscape 88
7.6.5 Geographical Landscape 91
7.6.6 Pipeline Analysis 91
7.7 Expert Panel Validation 91
7.8 Contact Us 91
7.9 Disclaimer 91

List of Tables


Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009 12
Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009 16
Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004 16
Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007 18
Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn’s Disease, 2007 19
Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011 21
Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn’s Disease, 2013 21
Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn’s Disease, 2012 22
Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn’s Disease , 2009 25
Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013 68
Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013 68
Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013 69
Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013 70
Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013 71
Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013 73
Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013 73
Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012 74
Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012–2019 74
Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012–2019 75
Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn’s Disease, Market Forecast, 2012–2019 75
Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012–2019 75
Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012–2019 76
Table 23: Gastrointestinal Therapeutics Market, US, Crohn’s Disease, Market Forecast, 2012–2019 76
Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012–2019 76
Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012–2019 77
Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn’s Disease, Market Forecast, 2012–2019 77
Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012–2019 77
Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012–2019 78
Table 29: Gastrointestinal Therapeutics Market, UK, Crohn’s Disease, Market Forecast, 2012–2019 78
Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012–2019 78
Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012–2019 79
Table 32: Gastrointestinal Therapeutics Market, France, Crohn’s Disease, Market Forecast, 2012–2019 79
Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012–2019 79
Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012–2019 80
Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn’s Disease, Market Forecast, 2012–2019 80
Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012–2019 80
Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012–2019 81
Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn’s Disease, Market Forecast, 2012–2019 81
Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012–2019 81
Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012–2019 82
Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn’s Disease, Market Forecast, 2012–2019 82
Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012–2019 82
Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012–2019 83
Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn’s Disease, Market Forecast, 2012–2019 83

List of Figures


Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007 20
Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006–2012 27
Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006–2012 28
Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006–2012 29
Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009–2012 30
Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008–2012 31
Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006–2012 32
Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013 35
Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013 36
Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012 38
Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013 40
Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013 41
Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013 43
Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline, 2013 45
Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Molecule Type, 2013 46
Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn’s Disease, Pipeline by Mechanism of Action, 2013 48
Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012–2019 51
Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012–2019 53
Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012–2019 55
Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012–2019 57
Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012–2019 59
Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006–2013 63
Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006–2013 64
Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006–2013 66
Figure 25: GBI Research Market Forecasting Model 90

Upcoming Reports:

Separation Systems For Commercial Biotechnology Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Separation of proteins and biomolecules such as DNA, RNA is an integral process during production of commercial biotechnology products. This requires use of variety of separating systems such as liquid chromatography, gas chromatography, microarray, membrane filtration, electrophoresis, magnetic separation and flow cytometry. The global market for the separation systems for commercial biotechnology market is growing rapidly owing to the increased demand for the biotechnological products, innovation and improvisation in the separation technology itself. The separation systems...
Vein Pattern Recognition Market - Global Industry Size, Market Share, Trends, Analysis, And Forecast, 2012 - 2018
By - Transparency Market Research
The wide acceptance of biometrics such as facial recognition, fingerprinting, iris recognition, and hand geometry have already stormed the global biometrics market. However, the new vein recognition biometrics technology, with its unique features, is expected to create its mark in the biometrics market. Of all the latest biometrics technologies, vein pattern recognition is one of the fastest growing new entrants in this market. The vein pattern recognition technology works on the principle of identification of the subcutaneous vein patterns in the hand. As the user places his or...
Touch Screen Technology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Touch screen technology acts as an interface between computers and users which provide an easy visual experience for interaction to the users. The popularity of touch screen technology in PCs, smartphones, mobile phones, tablets and in many other information devices is gaining momentum. Touch screen technology provides strong control on the device and hassle free interactivity. There are various types of touch screen available in the market such as capacitive touch screen, resistive touch screen, optical touch screen, surface acoustic wave and infrared touch screen. Touch screen...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...